Floatz logo

Clofarabine

Lymphoid Malignancies

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Lymphoid Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
Abt-263
AbbVie
Phase 1/2B
Pralatrexate
Jennifer Amengual
Phase 1/2CCC
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
National Cancer Institute (NCI)
Phase 1/2CCC
Venetoclax
National Cancer Institute (NCI)
Phase 1/2CCC

View all 21 →

Same molecule, other indications

Clofarabine is also rated in:

acute myeloid leukemia with 11q23 abnormalitiesDormant
BB
Indicative ·
70 / 100
View asset →
acute myeloid leukemia, del(5q31-q32)Dormant
BB
Indicative ·
70 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →